Literature DB >> 15266208

Genetic testing for alpha1-antitrypsin deficiency.

Charlie Strange1, Ryan Dickson, Cindy Carter, Matthew J Carpenter, Brian Holladay, Ryan Lundquist, Mark L Brantly.   

Abstract

PURPOSE: The Alpha Coded Testing Study investigated the risks, benefits, and psychological impact of home genetic testing for alpha1-antitrypsin deficiency.
METHODS: In the study, 996 adult individuals requested and returned a home-administered, confidential, fingerstick blood test.
RESULTS: Individuals highly rated the benefits of establishing a diagnosis (82%), helping family members (86%), and anticipating peace of mind (79%). 78% of 239 current smokers reported a high likelihood of smoking cessation if diagnosed with AATD. After testing, more than 60% indicated that they would share the results with family and physicians but < 30% would share results with insurance companies.
CONCLUSIONS: Confidential home testing for genetic disorders requires a comprehensive program of participant support.

Entities:  

Mesh:

Year:  2004        PMID: 15266208     DOI: 10.1097/01.gim.0000132669.09819.79

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  10 in total

1.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Authors:  Charlie Strange; Robert M Senior; Frank Sciurba; Scott O'Neal; Alison Morris; Stephen R Wisniewski; Russell Bowler; Harry S Hochheiser; Michael J Becich; Yingze Zhang; Joseph K Leader; Barbara A Methé; Naftali Kaminski; Robert A Sandhaus
Journal:  Ann Am Thorac Soc       Date:  2015-10

2.  The Alpha-1 Association Genetic Counseling Program: an innovative approach to service.

Authors:  Dawn McGee; Charlie Strange; Rebecca McClure; Laura Schwarz; Marlene Erven
Journal:  J Genet Couns       Date:  2011-03-19       Impact factor: 2.537

Review 3.  Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Authors:  Diana Crossley; Robert Stockley; Elizabeth Sapey
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

4.  Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.

Authors:  Adam Wanner; Stephen C Groft; J Russell Teagarden; Jeffrey Krischer; Barry R Davis; Christopher S Coffey; David H Hickam; Jeffrey Teckman; David R Nelson; Michael L McCaleb; Rohit Loomba; Charlie Strange; Robert A Sandhaus; Mark Brantly; Jonathan M Edelman; Albert Farrugia
Journal:  Chronic Obstr Pulm Dis       Date:  2015-04-28

5.  Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?

Authors:  Dawn McGee; Laura Schwarz; Rebecca McClure; Lauren Peterka; Farshid Rouhani; Mark Brantly; Charlie Strange
Journal:  Pulm Med       Date:  2010-06-28

Review 6.  Impact of genetic risk assessment on nutrition-related lifestyle behaviours.

Authors:  Jacqueline A Vernarelli
Journal:  Proc Nutr Soc       Date:  2012-10-25       Impact factor: 6.297

7.  The impact of social contexts in testing for alpha-1 antitrypsin deficiency: the roles of physicians and others.

Authors:  Robert Klitzman
Journal:  Genet Test Mol Biomarkers       Date:  2009-04

Review 8.  Detection of alpha-1 antitrypsin deficiency: the past, present and future.

Authors:  Mark Brantly; Michael Campos; Angela M Davis; Jeanine D'Armiento; Kenneth Goodman; Kathi Hanna; Miriam O'Day; John Queenan; Robert Sandhaus; James Stoller; Charlie Strange; Jeffrey Teckman; Adam Wanner
Journal:  Orphanet J Rare Dis       Date:  2020-04-19       Impact factor: 4.123

9.  Relationship between alpha-1 antitrypsin deficiency and obstructive sleep apnea.

Authors:  Lindsay Megenhardt; Sarah Ransdell; Jodi Clark-LoCascio; Roy A Pleasants; Mark Brantly; Charlie Strange
Journal:  Sleep Breath       Date:  2021-04-30       Impact factor: 2.816

10.  Lung cancer susceptibility model based on age, family history and genetic variants.

Authors:  Robert P Young; Raewyn J Hopkins; Bryan A Hay; Michael J Epton; Graham D Mills; Peter N Black; Heather D Gardner; Richard Sullivan; Gregory D Gamble
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.